This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by RAYMOND, J. P. Articles by VALLUÉ, G. Search for Related Content PubMed PubMed Citation Articles by RAYMOND, J. P. Articles by VALLUÉ, G.

Temporary Ovarian Failure in Thyroid Cancer Patients after Thyroid Remnant Ablation with Radioactive Iodine

Service d'Endocrinologie F-75877 Paris Cedex 18
Service de Médecine Nucléaire, Hôpital Bich F-75877 Paris Cedex 18
Service de Biophysique, Faculté Necker F-75730 Paris Cedex 15, France

Address requests for reprints to: Dr. J. P. Raymond, Service d'Endocrinologie, Hôpital Bichat, 46 rue Henri-Huchard, F-75877 Paris Cedex 18, France.

We studied ovarian function retrospectively in 66 women who had regular menstrual cycles before undergoing complete thyroidectomy for differentiated thyroid cancer and subsequent thyroid remnant ablation with ¹³¹I. Eighteen women developed temporary amenorrhea accompanied by increased serum gonadotropin concentrations during the first year after ¹³¹I therapy. No correlation was found between the radioactive iodine dose absorbed, thyroid uptake before treatment, oral contraceptive use, or thyroid autoimmunity. Only age was a determining factor, with the older women being the most affected. We conclude that radioiodine ablation therapy is followed by transient ovarian failure, especially in older women.

Received August 4, 1988.

This article has been cited by other articles:

				P. W. Rosario, M. A. R. Borges, and S. Purisch Preparation with Recombinant Human Thyroid-Stimulating Hormone for Thyroid Remnant Ablation with 131I Is Associated with Lowered Radiotoxicity J. Nucl. Med., November 1, 2008; 49(11): 1776 - 1782. [Abstract] [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]

				L Vini, S Hyer, A Al-Saadi, B Pratt, and C Harmer Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer Postgrad. Med. J., February 1, 2002; 78(916): 92 - 93. [Abstract] [Full Text] [PDF]

				C. Ceccarelli, W. Bencivelli, D. Morciano, A. Pinchera, and F. Pacini 131I Therapy for Differentiated Thyroid Cancer Leads to an Earlier Onset of Menopause: Results of a Retrospective Study J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3512 - 3515. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri and R. T. Kloos Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1447 - 1463. [Full Text]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				M. Schlumberger Use of Radioactive Iodine in Patients with Papillary and Follicular Thyroid Cancer: Towards A Selective Approach J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4201 - 4203. [Full Text]

				M. J. Schlumberger Papillary and Follicular Thyroid Carcinoma N. Engl. J. Med., January 29, 1998; 338(5): 297 - 306. [Full Text] [PDF]